SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining momentum as investors react to a series of strategic milestones, including expanded partnerships with U.S. Department of Energy national labs and a high-profile presence at the NVIDIA GTC conference. Community sentiment is deeply divided between long-term believers who are aggressively accumulating shares due to the company's defense-focused quantum hardware, and skeptics who are wary of recent downward price action following the company's de-SPAC process.

Asana, Inc. engages in the business of developing a work management platform that helps organizations orchestrate work from daily tasks to cross-functional strategic initiatives. The company was founded by Dustin Moskovitz and Justin Michael Rosenstein on December 16, 2008 and is headquartered in San Francisco, CA.

Asana Inc - Ordinary Shares - Class A

Asana Inc

Asana is attracting attention due to a combination of persistent insider buying from the CEO and a potential turnaround narrative following a recent leadership transition. While some investors view the stock's discounted valuation and insider activity as a strong signal for a rebound, others remain skeptical, citing ongoing profitability challenges and intense competition from AI-integrated enterprise software.

Tria is a self-custodial neobank and cross-chain payments infrastructure designed to make onchain money usable in everyday life. It combines card spending, trading, and earning in a single account experience, so users can move value across chains without manually bridging assets, switching networks, or managing chain-specific steps. Under the hood, Tria routes every action through BestPath, an ultra-fast routing and execution layer that takes an intent like “spend,” “swap,” “send,” or “earn” and completes it end-to-end on the optimal path. Tria operates in two modes: a consumer app that includes a Visa-powered card, spot swaps, perpetual futures, and Earn vaults, and a developer and institutional layer that integrates with protocols and ecosystems to embed Tria’s execution rails wherever value already moves. The end goal is simple: one continuous flow for money across chains, with self-custody by default and a product experience that feels effortless for normal users worldwide.

TRIA

TRIA is gaining momentum as investors highlight its rapid user growth and real-world utility as a self-custodial neobank, while anticipation builds around potential upcoming partnerships with major online banks. The community is actively discussing its strong trading volumes and consistent chart consolidation, viewing the project as a unique, profitable player in the evolving blockchain financial space.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is in the spotlight as investors process strong second-quarter earnings that topped expectations, leading the company to raise its full-year guidance even as the defense sector faces ongoing scrutiny over executive compensation and capital allocation policies. The community is actively debating the impact of increased military spending priorities against recent regulatory pressures that threaten to limit dividends and buybacks for major defense contractors.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors weigh strong earnings and capital return strategies against legal risks and broader sector concerns about credit quality. The community is actively discussing the bank's aggressive branch expansion, its stance on private credit stress, and the impact of ongoing regulatory and legal scrutiny on its long-term outlook.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is trending as investors digest a mix of regulatory uncertainty, potential legislative developments, and high-profile institutional interest from figures like Bill Ackman and Michael Burry. The community is actively debating the likelihood of an end to government conservatorship and an eventual uplisting to the NYSE, with sentiment sharply divided between long-term holders expecting a massive valuation reset and skeptics concerned about government delays and ongoing policy inertia.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) remains a focal point as investors grapple with extreme geopolitical risk and supply disruptions in the Strait of Hormuz, driving crude oil toward historic highs. Community sentiment is deeply divided between traders capitalizing on the energy-sector rotation and those bracing for the broader economic damage a sustained oil shock could inflict on the S&P 500.

Global X Funds - Global X Uranium ETF

Global X Uranium ETF

The uranium sector is currently oscillating between strong long-term fundamental demanddriven by AI data center energy needs and government push for nuclear independenceand short-term volatility stemming from corrective technical structures. While community sentiment remains largely bullish, investors are actively debating whether to buy current pullbacks or await further consolidation as the ETF navigates a complex macro environment.

Global X Funds - Global X Copper Miners ETF

The community is closely watching the Global X Copper Miners ETF ($COPX) as investors debate whether recent volatility represents a healthy accumulation period before a structural bull market or a deeper correction linked to broader economic jitters. While some traders are expressing frustration over recent price weakness, many remain focused on a long-term bullish thesis driven by supply-side deficits and the critical role copper plays in AI infrastructure, defense, and grid modernization.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense market volatility as investors weigh the stock's recent price depreciation against strong long-term fundamentals and growing enterprise demand for AI-integrated Zero Trust security. While the community remains sharply divided, with some traders citing 'AI disruption' fears and heavy short interest as catalysts for the downward trend, others are actively viewing these levels as an institutional accumulation opportunity ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This Week’s Hottest Themes: Biotech (RFK Jr. Meddling), Space (Trump's Space Force),&nbsp; AI (The Theme of the Year)&nbsp;WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in sectors actively drawing capital. This targeted approach, combined with real-time news surveillance, helps us uncover stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.Here's a list of today's most important names:1. Cassava Sciences (NASDAQ: SAVA)Background: Cassava Sciences is a clinical-stage biotechnology company focused on Alzheimer’s disease. Its investigational drug, Simufilam, has been central to its research efforts.The News: Cassava's stock took a dramatic plunge after disappointing Phase 3 trial results for Simufilam, followed by a social media storm triggered by Martin Shkreli’s scathing critique of the drug’s efficacy. Shkreli, calling Simufilam’s mechanism “implausible,” encouraged short-sellers, predicting a sharp decline in the stock. The failure of the trial and Shkreli’s influence sent shares tumbling by more than 85%, from nearly $30 per share to under $5.What It Means: This setback emphasizes the significant risks in Alzheimer's drug development. With most Alzheimer’s trials failing, investors now question the credibility of Cassava’s lead drug. While the company still has resources to pivot, the stock’s credibility has been deeply shaken, and the road ahead is uncertain.Stock Reaction: Yesterday the stock opened at $30 but closed near $5, reflecting a swift and steep sell-off. The market’s reaction shows how quickly investor sentiment can turn negative on biotech stocks, particularly in high-risk, high-reward sectors like Alzheimer’s treatment.&nbsp;2. Poseida Therapeutics (NASDAQ: PSTX)Background: Poseida is a biopharmaceutical company specializing in gene therapies, particularly CAR-T treatments for cancer.The News: Poseida announced a significant partnership with Roche, securing $110 million upfront and up to $1 billion in potential milestones. This deal is aimed at accelerating Poseida's CAR-T therapies and other cell and gene therapy technologies.What It Means: This collaboration is a major validation for Poseida’s technology, especially in the competitive CAR-T space, which has attracted attention due to its potential to treat cancers. The cash infusion from Roche is expected to fuel further research and development.Stock Reaction: Poseida opened at $9.26, up over 200%, rising slightly to close at $9.38. The market responded favorably to the news, viewing the Roche deal as a solid indication of Poseida’s future potential in the cancer treatment landscape.&nbsp;3. KULR Technology Group (NYSE: KULR)Background: KULR specializes in thermal management technologies for energy storage and aerospace.The News: KULR Technology Group has received a U.S. Navy contract to develop its Internal Short Circuit (ISC) technology to operate at higher temperatures. This upgrade is important for both military and commercial applications, especially in aviation where it aligns with safety standards. The ISC devices, originally developed with NASA and NREL, simulate controlled thermal runaway in lithium-ion cells for more accurate and safer testing of battery behavior in extreme conditions.What It Means: The Navy contract could serve as a major stepping stone for KULR, providing the company with exposure to one of the most demanding industries for thermal solutions. This deal not only enhances KULR’s credibility but may also open doors for similar partnerships in the aerospace and defense sectors.Stock Reaction: The stock opened at $0.80 and climbed another 20% reaching $0.96 by mid-morning on volume that is 1,000%+ higher than average.&nbsp;4. POET Technologies (NASDAQ: POET)Background: POET is a leader in photonics technology, designing advanced semiconductor solutions aimed at AI, telecommunications, and data storage.The News: POET Technologies (NASDAQ: POET) is ramping up production of its optical engines to meet the increasing demand from AI applications. A recent report highlighted that while many companies in the UK are adopting AI, few have integrated it into their manufacturing processes, which could hinder innovation and productivity. The report suggests that government support and regulations could help accelerate AI adoption in industries.What It Means: As AI applications continue to expand, POET’s new platform could be a game-changer. The optical interposer aims to address the bottlenecks in data processing by enabling faster, more efficient communication between chips, which is crucial for AI and big data.Stock Reaction: POET opened at $4.38 and rose to $5.35 (up 22%) by mid-day on volume 3x higher than average.&nbsp;5. SurgePays (NASDAQ: SURG)Background: SurgePays provides financial services and prepaid wireless solutions for underserved markets.The News:&nbsp;SurgePays (SURG) has integrated its ClearLine marketing platform with PAX smart payment terminals, allowing merchants to deliver real-time promotions and offers during transactions. This integration leverages existing hardware to enhance customer engagement and streamline marketing efforts, helping retailers boost loyalty and sales. SurgePays aims to scale its retail presence by utilizing PAX's wide reach in the payment terminal industry.What It Means: SurgePays continues to capitalize on the significant need for affordable financial services and wireless solutions in underserved communities. This strong performance suggests the company’s business model is scaling effectively, positioning it well for future growth.Stock Reaction: SurgePays opened at $2.00 and surged to $2.20, up 10%, trading average volume.&nbsp;6. TOYO Ventures Holdings (NASDAQ: TOYO)Background: TOYO Co., Ltd. is a solar solutions company focused on becoming a full-service provider in the global market. It integrates all stages of the solar power supply chain, including wafer and silicon production, solar cell manufacturing, and photovoltaic module production. TOYO is positioned to produce high-quality solar cells at a competitive scale and cost.The News: TOYO Co., Ltd (Nasdaq: TOYO) has secured a $150 million contract to supply high-efficiency solar cells to a major solar module manufacturer. The agreement will support solar module production in India and the U.S., leveraging TOYO’s advanced manufacturing capabilities in Vietnam and Ethiopia. This contract highlights the company's commitment to sustainable energy and the global shift towards renewable resources.What It Means: The $150 million contract is a major win for TOYO Co., Ltd, solidifying its role as a key player in the solar energy sector. It highlights the company’s advanced manufacturing capabilities and global reach, particularly in India and the U.S. For the market, the deal signals continued growth in the solar industry, boosting confidence in renewable energy technologies and potentially attracting more investment. TOYO’s expanded presence in key markets could strengthen its competitive position as demand for efficient solar cells rises..Stock Reaction: Shares opened at $5.56, up 39% to retrace to $4.50 by mid-morning and closing at $5.41 on eye-poping 1,500x average volume.&nbsp;&nbsp;7. Anavex Life Sciences (NASDAQ: AVXL)Background:&nbsp;Anavex Life Sciences develops treatments for neurodegenerative disorders like Alzheimer's and Parkinson's. Its lead drug, ANAVEX®2-73, has shown positive results in Phase 2 trials, while the company is also developing ANAVEX®3-71 for Alzheimer's.The News:Anavex Life Sciences has submitted a Marketing Authorization Application (MAA) for its drug, blarcamesine (ANAVEX®2-73), to the European Medicines Agency (EMA) for the treatment of Alzheimer’s disease. Blarcamesine, an orally administered small molecule, showed significant clinical improvement in patients over 48 weeks, with better efficacy than approved therapies and a slower rate of neurodegeneration in early Alzheimer's patients. Its safety profile eliminates the need for routine MRI monitoring, making it a promising treatment option.What It Means:&nbsp;The MAA submission for blarcamesine to the EMA is a positive development for Anavex Life Sciences, potentially boosting its stock if approved. If successful, blarcamesine could open new revenue streams and strengthen investor confidence. For the broader market, this signals progress in Alzheimer’s treatment, potentially drawing more investment into biotech, especially in neurodegenerative diseases.Stock Reaction: Anavex opened at $10.30 up 10% from Monday's close, but cratered almost 20% from that high by mid-afternoon closing nearly flat from the previous day's close on slightly higher than average volume.&nbsp;&nbsp;Be The First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST&nbsp;SpaceMobile (NASDAQ: ASTS) which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WealthyVC">Follow us on Twitter</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/wealthyventurecapital/">Follow us on Instagram</a> <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/TheWealthyVentureCapitalist/?locale=zh_CN">Follow us on Facebook</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Your Daily Digest of Stocks That Released News Which Moved the Market

Equity

Shares of Poseida Therapeutics Inc. (<a class="mention" data-mention="$PSTX" data-symbol-id="PSTX" href="https://stocktwits.com/symbol/PSTX" target="_blank">$PSTX</a>) surged over 200% on Tuesday, reaching levels not seen since August 2021, after the company announced its acquisition by Roche Holdings ($RHHBY) in a deal valued at up to $1.5 billion.The stock was the top gainer across U.S. markets early on Tuesday and was among the top 10 trending symbols on Stocktwits.Under the agreement, Poseida stockholders will receive $9.00 per share in cash at closing, along with a non-tradable contingent value right (CVR) of up to $4.00 per share, contingent upon achieving specific milestones.&nbsp;The deal underscores Roche’s interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory (TSCM) cells.“Poseida has demonstrated the unique ability of its proprietary non-viral technology platform to create allogeneic, TSCM-rich CAR-T therapies with the potential to improve clinical outcomes and expand access to this important class of medicines,” said Poseida CEO Kristin Yarema.“Most recently, this was highlighted by the compelling interim clinical data for P-BCMA-ALLO1 in patients with multiple myeloma.”Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.Wall Street analysts reportedly responded with several downgrades for Poseida, citing the definitive valuation set by the acquisition terms.H.C. Wainwright, William Blair, BTIG, and Cantor Fitzgerald all downgraded the stock to ‘Neutral’ or equivalent ratings, noting the fair terms of the $13 per share offer, which includes both upfront cash and milestone-dependent payouts.The acquisition builds on a collaboration between the two companies that began in 2022, focused on CAR-T cell therapies for hematologic malignancies.&nbsp;The merger is expected to close in the first quarter of 2025, with Poseida and its employees set to join Roche’s Pharmaceuticals Division.Retail sentiment on Stocktwits has also turned ‘extremely bullish’, with users highlighting the premium payout as a significant win for shareholders.<stembedurl>https://stocktwits.com/lecorb/message/594107339</stembedurl><stembedurl>https://stocktwits.com/symbol/PSTX</stembedurl>Poseida shares, which had lost over 15% year-to-date before the announcement, are now poised for a dramatic turnaround, driven by investor optimism about the acquisition.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intc-stock-rises-on-finalizing-chips-act-funding/cJIWnjbRgs">Intel Stock Rises As Chipmaker Secures $7.9B CHIPS Act Funding From Team Biden: Retail Hopes Improve</a>

Roche’s acquisition also includes Poseida’s cell therapy candidates, manufacturing capabilities, and technology platform.

Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric

The deal underscores Roche's interest in Poseida’s proprietary non-viral platform, which enables the development of allogeneic CAR-T therapies enriched with T stem cell memory cells.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

PSTX
Poseida Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTX News

PSTXPoseida Therapeutics Inc